Industrial Bioprocessing Market Global Report 2026

The industrial bioprocessing market size has grown strongly in recent years. It will grow from $18.95 billion in 2025 to $20.61 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to growth in pharmaceutical manufacturing demand, expansion of industrial enzyme production, increasing adoption of fermentation based processes, rising investments in biotechnology research facilities, development of large scale biomanufacturing infrastructure.

The industrial bioprocessing market size is expected to see strong growth in the next few years. It will grow to $29.05 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to rising demand for bio based chemicals and fuels, expansion of precision medicine and biologics production, increasing focus on cost efficient biomanufacturing processes, adoption of next generation cell culture technologies, growing demand for sustainable industrial production alternatives. Major trends in the forecast period include increasing adoption of single use bioprocessing systems for reduced contamination risk, rising demand for high efficiency downstream purification techniques, expansion of large scale fermentation capacity in industrial manufacturing, growing preference for modular and flexible bioreactor designs, increasing focus on regulatory compliant bio production workflows ensuring product consistency.

The rising demand for biologics and biopharmaceuticals is expected to propel the growth of the industrial bioprocessing market going forward. Biologics and biopharmaceuticals are complex therapeutic products developed using living cells or organisms to treat a wide range of medical conditions through biological pathways. The demand for biologics and biopharmaceuticals is increasing due to the growing prevalence of chronic diseases, as these advanced therapies offer highly targeted and effective treatment options with improved clinical outcomes compared to traditional medications. Industrial bioprocessing supports biologics and biopharmaceuticals production by enabling the large-scale cultivation of cells and microorganisms required to manufacture complex biological medicines efficiently, consistently, and with high purity through controlled fermentation and downstream processing methods. For instance, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, the United States had 33 FDA-approved biosimilar products as of January 2022, of which 21 were commercially available. By 2023, the number of FDA-approved biosimilars had increased to 40, with 25 available in the market. Therefore, the rising demand for biologics and biopharmaceuticals is driving the growth of the industrial bioprocessing market.

Major companies operating in the industrial bioprocessing market are focusing on establishing strategic partnerships to improve upstream processing efficiency, accelerate process intensification, and enhance biomanufacturing productivity. Strategic partnerships are collaborative arrangements between organizations that combine technologies, expertise, and resources to drive innovation, improve operational performance, and expand capabilities in industrial bioprocessing. For instance, in August 2023, Sartorius AG, a Germany-based life sciences company, partnered with Repligen Corporation, a US-based bioprocessing technology company, to introduce an integrated solution that combines the Biostat STR bioreactor with XCell ATF technology for upstream process intensification. The system is designed to support high-density cell culture and intensified perfusion processes, increasing productivity and efficiency in industrial bioprocessing applications used in the manufacture of biologics, including monoclonal antibodies and other therapeutic proteins.

In August 2024, Merck KGaA, a Germany-based science and technology company, acquired Mirus Bio LLC for $600 million. Through this acquisition, Merck KGaA sought to strengthen its viral vector bioprocessing capabilities, broaden its cell and gene therapy manufacturing portfolio, and enhance its end-to-end solutions for advanced biologics production. Mirus Bio LLC is a US-based biotechnology company that provides upstream bioprocessing solutions for cell and gene therapy manufacturing.

Major companies operating in the industrial bioprocessing market are Thermo Fisher Scientific; Danaher Corporation; Merck KGaA; Sartorius Aktiengesellschaft; Avantor Inc.; Corning Inc.; GEA Group Aktiengesellschaft; Repligen Corporation; Entegris Inc.; Eppendorf SE; Parker Hannifin; Hamilton Company; ZETA Holding GmbH; Glatt Ingenieurtechnik GmbH; Rentschler Biopharma SE; Meissner Filtration Products Inc.; Shanghai Tofflon Science and Technology Co. Ltd.; ABEC Inc.; Codexis Inc.; PBS Biotech Inc.; Broadley-James Corporation; INFORS HT; CerCell ApS; Wacker Biotech GmbH; BPC Instruments AB; OmniBRx Biotechnologies Pvt. Ltd.; Bailun Biotechnology Co. Ltd.; Adolf Kühner AG; Fermenter Technologies Pty Ltd.

North America was the largest region in the industrial bioprocessing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the industrial bioprocessing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the industrial bioprocessing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The industrial bioprocessing market consists of revenues earned by entities by providing services such as cell line development, bioprocess scale-up services, and technology transfer services. The market value includes the value of related goods sold by the service provider or included within the service offering. The industrial bioprocessing market also includes sales of bioreactors and fermenters, filtration systems, and single-use bioprocessing systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The industrial bioprocessing market research report is one of a series of new reports that provides industrial bioprocessing market statistics, including industrial bioprocessing industry global market size, regional shares, competitors with a industrial bioprocessing market share, detailed industrial bioprocessing market segments, market trends and opportunities, and any further data you may need to thrive in the industrial bioprocessing industry. This industrial bioprocessing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.